BEAM
Beam TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The core bull case is still program-driven rather than quarter-driven: BEAM-302 now has a defined pivotal path, risto-cel has increasingly mature clinical and operational data, and February financing reduced near-term balance-sheet pressure. As of May 4, 2026, Beam’s investor site still did not show a confirmed Q1 2026 earnings release or earnings 8-K, so the thesis remains anchored to prior primary-source program updates rather than fresh quarterly commentary [#IR-2026-05-04].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +15.0.
What can break
As of May 4, 2026, Beam’s investor-relations pages still showed April 1, 2026 as the latest press release and March 25, 2026 as the latest webcast, so a Q1 2026 earnings release or earnings 8-K was not confirmed in primary sources [#IR-2026-05-04].
Momentum
43
Value
41
Sentiment
72
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $35.00 · Bull $46.00 · Bear $22.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $50.92
Why
Momentum43 · Δ7d -25.9
Value41 · Δ7d +0.0
Sentiment72 · Δ7d +15.0
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
43
26% active weight
Current posture
7d trendSoftening
Δ7d
-25.9
Δ21d
-46.1
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
72
34% active weight
Current posture
7d trendImproving
Δ7d
+15.0
Δ21d
+23.1
Why this grade
Composite grade C. Momentum 42.5 / Value 41.1 / Sentiment 72.0
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$2.83B
Beta
2.12
Shares Out
102.88M
P/E (TTM) · Derived
-34.0
P/S (TTM)
48.90
P/FCF (TTM) · Derived
-7.40
Rev YoY
+324.9%
EPS YoY
-25.8%
Gross Margin
+86.4%
Op Margin
-837.1%
Net Debt
-$1.09B
Current Ratio
16.99
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology